LinkOPH

PHILADELPHIA — Abnormal dark adaptation is a potential marker of subclinical macular dysfunction among patients who are otherwise deemed good candidates for multifocal IOL implantation, according to a presentation here. “In early [age-related macular degeneration], Snellen visual acuity is frequently undisturbed, but problems with night vision and vision in low-light conditions are frequently reported by patients.” Marta McKeague, MD, said at the Wills Eye Alumni Conference. The symptoms are similar to cataract symptoms, making it important to differentiate between the two, she added.

Read more →

The Raindrop near vision inlay yielded significant improvements in near and intermediate visual acuity in patients with emmetropic presbyopia, according to a study. The prospective FDA investigational device exemption clinical trial included 373 eyes f…

Read more →

ThromboGenics has signed an exclusive licensing agreement with Galapagos to develop and commercialize integrin antagonists to treat diabetic eye disease, according to a press release. ThromboGenics will pay a 1 million upfront technology transfer payment to Galapagos, and Galapagos will receive development and commercial milestone payments and royalties based on any future net sales from products that originated from Galapagos’ library of integrin antagonists.

Read more →

At OSN New York, John A. Hovanesian, MD, FACS, discusses how the use of follow-up care software in the ophthalmic practices can increase patient satisfaction.

Read more →